|
1
|
McBride OW, Merry D and Givol D: The gene
for human p53 cellular tumor antigen is located on chromosome 17
short arm (17p13). Proc Natl Acad Sci USA. 83:130–134. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Strachan T and Read AP: Human molecular
genetics. 2nd. Wiley-Liss; New York, NY: 1999, PubMed/NCBI
|
|
3
|
Nakao M, Matsuo K, Ito H, Shitara K,
Hosono S, Watanabe M, Ito S, Sawaki A, Iida S, Sato S, et al: ABO
genotype and the risk of gastric cancer, atrophic gastritis, and
Helicobacter pylori infection. Cancer Epidemiol Biomarkers
Prev. 20:1665–1672. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marte B: Cancer: Super p53. Nature.
420:2792002. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ventura A, Kirsch DG, McLaughlin ME,
Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R
and Jacks T: Restoration of p53 function leads to tumour regression
in vivo. Nature. 445:661–665. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hong H, Takahashi K, Ichisaka T, Aoi T,
Kanagawa O, Nakagawa M, Okita K and Yamanaka S: Suppression of
induced pluripotent stem cell generation by the p53-p21 pathway.
Nature. 460:1132–1135. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Misra C, Majumder M, Bajaj S, Ghosh S, Roy
B and Roychoudhury S: Polymorphisms at p53, p73, and MDM2 loci
modulate the risk of tobacco associated leukoplakia and oral
cancer. Mol Carcinog. 48:790–800. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Haupt Y, Maya R, Kazaz A and Oren M: Mdm2
promotes the rapid degradation of p53. Nature. 387:296–299. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Honda R, Tanaka H and Yasuda H:
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.
FEBS Lett. 420:25–27. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kubbutat MH, Jones SN and Vousden KH:
Regulation of p53 stability by Mdm2. Nature. 387:299–303. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Momand J and Zambetti GP: Mdm-2: ‘big
brother’ of p53. J Cell Biochem. 64:343–352. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bond GL, Hu W, Bond EE, Robins H, Lutzker
SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, et al: A
single nucleotide polymorphism in the MDM2 promoter attenuates the
p53 tumor suppressor pathway and accelerates tumor formation in
humans. Cell. 119:591–602. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Menin C, Scaini MC, De Salvo GL, Biscuola
M, Quaggio M, Esposito G, Belluco C, Montagna M, Agata S, D'Andrea
E, et al: Association between MDM2-SNP309 and age at colorectal
cancer diagnosis according to p53 mutation status. J Natl Cancer
Inst. 98:285–288. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ohmiya N, Taguchi A, Mabuchi N, Itoh A,
Hirooka Y, Niwa Y and Goto H: MDM2 promoter polymorphism is
associated with both an increased susceptibility to gastric
carcinoma and poor prognosis. J Clin Oncol. 24:4434–4440. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yoon YJ, Chang HY, Ahn SH, Kim JK, Park
YK, Kang DR, Park JY, Myoung SM, Kim DY, Chon CY and Han KH: MDM2
and p53 polymorphisms are associated with the development of
hepatocellular carcinoma in patients with chronic hepatitis B virus
infection. Carcinogenesis. 29:1192–1196. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Miller SA, Dykes DD and Polesky HF: A
simple salting out procedure for extracting DNA from human
nucleated cells. Nucleic Acids Res. 16:12151988. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yilmaz M, Tas A, Kacan T, Sari M and Silig
Y: Is there a relation between murine double minute 2 T309G
polymorphism and lung cancer risk in the Turkish population? Turk J
Biochem. 42:123–129. 2017.
|
|
19
|
Crew KD and Neugut AI: Epidemiology of
upper gastrointestinal malignancies. Semin Oncol. 31:450–464. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Geng JS, Song HT and Wang WR: Diversity of
invasiveness and matrix metalloproteinases expression profile of
human gastric carcinoma xenografted in different tissue
environments. Zhonghua Bing Li Xue Za Zhi. 33:53–56. 2004.(In
Chinese). PubMed/NCBI
|
|
21
|
Brady M, Vlatkovic N and Boyd MT:
Regulation of p53 and MDM2 activity by MTBP. Mol Cell Biol.
25:545–553. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Freedman DA, Wu L and Levine AJ: Functions
of the MDM2 oncoprotein. Cell Mol Life Sci. 55:96–107. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hirata H, Hinoda Y, Kikuno N, Kawamoto K,
Suehiro Y, Tanaka Y and Dahiya R: MDM2 SNP309 polymorphism as risk
factor for susceptibility and poor prognosis in renal cell
carcinoma. Clin Cancer Res. 13:4123–4129. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Terry K, McGrath M, Lee IM, Buring J and
De Vivo I: MDM2 SNP309 is associated with endometrial cancer risk.
Cancer Epidemiol Biomarkers Prev. 17:983–986. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Olsson H, Hultman P, Rosell J, Söderkvist
P and Jahnson S: MDM2 SNP309 promoter polymorphism and p53
mutations in urinary bladder carcinoma stage T1. BMC Urol.
13:52013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang GX, Li YQ and Pan XL: Polymorphism
of MDM2 promoter, regulated by Helicobacter pylori
lipopolysaccharide, is associated with both an increased
susceptibility to gastric carcinoma and poor prognosis in Chinese
patients. J Gastroenterol Hepatol. 26:2802011.
|
|
27
|
Wang X, Yang J, Ho B, Yang Y, Huang Z,
Zhang Z and Zhang G: Interaction of Helicobacter pylori with
genetic variants in the MDM2 promoter, is associated with gastric
cancer susceptibility in Chinese patients. Helicobacter.
14:114–119. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cho YG, Choi BJ, Song JH, Kim CJ, Cao Z,
Nam SW, Lee JY and Park WS: No association of MDM2 T309G
polymorphism with susceptibility to Korean gastric cancer patients.
Neoplasma. 55:256–260. 2008.PubMed/NCBI
|
|
29
|
Pan X, Li Y, Feng J, Wang X, Hao B, Shi R
and Zhang G: A functional polymorphism T309G in MDM2 gene promoter,
intensified by Helicobacter pylori lipopolysaccharide, is
associated with both an increased susceptibility and poor prognosis
of gastric carcinoma in Chinese patients. BMC Cancer. 13:1262013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen W, Wu Q and Ren H: Meta-analysis of
associations between MDM2 SNP309 polymorphism and gastric cancer
risk. Biomed Rep. 2:105–111. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Er LM, Zhang LW, Niu WW, Xu ZB, Du CQ, Gao
Y, Wang SP and Yuan L: Relation of MDM2 gene polymorphism and
Helicobacter pylori infection to gastric cardiac carcinoma.
Lin Chuang Hui Cui. 24:1594–1597. 2009.(In Chinese).
|
|
32
|
Tian X, Tian Y, Ma P, Sui C-G, Meng F-D,
Li Y, Fu L-Y, Jiang T, Wang Y, Ji FJ, et al: Association between
MDM2 SNP309 T>G and risk of gastric cancer: A meta-analysis.
Asian Pac J Cancer Prev. 14:1925–1929. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang M, Guo Y, Zhang X, Miao X, Tan W, Sun
T, Zhao D, Yu D, Liu J and Lin D: Interaction of P53 Arg72Pro and
MDM2 T309G polymorphisms and their associations with risk of
gastric cardia cancer. Carcinogenesis. 28:1996–2001. 2007.
View Article : Google Scholar : PubMed/NCBI
|
